Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 14,400 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Jean-Luc M. Lemercier sold 14,400 shares of the business's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares of the company's stock, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Edwards Lifesciences Trading Down 0.3 %

EW stock traded down $0.30 during mid-day trading on Monday, reaching $92.40. The company had a trading volume of 2,667,004 shares, compared to its average volume of 3,989,706. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The company has a market capitalization of $55.62 billion, a PE ratio of 40.17, a price-to-earnings-growth ratio of 4.59 and a beta of 1.05. The firm has a 50 day moving average of $89.03 and a 200 day moving average of $77.18. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period last year, the firm earned $0.64 earnings per share. The company's quarterly revenue was up 13.3% on a year-over-year basis. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Advisors Asset Management Inc. grew its holdings in Edwards Lifesciences by 0.3% during the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company's stock worth $5,127,000 after acquiring an additional 117 shares in the last quarter. Apollon Wealth Management LLC grew its holdings in Edwards Lifesciences by 1.0% during the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company's stock worth $1,033,000 after acquiring an additional 119 shares in the last quarter. Geller Advisors LLC grew its holdings in Edwards Lifesciences by 6.5% during the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company's stock worth $231,000 after acquiring an additional 120 shares in the last quarter. Martin Capital Advisors LLP grew its holdings in Edwards Lifesciences by 0.5% during the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company's stock worth $1,944,000 after acquiring an additional 128 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC grew its holdings in Edwards Lifesciences by 0.8% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company's stock worth $1,293,000 after acquiring an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on EW shares. Citigroup upped their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. Truist Financial boosted their price target on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, December 22nd. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $82.00 to $95.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 7th. Stifel Nicolaus boosted their price target on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a "hold" rating in a research note on Wednesday, February 7th. Finally, Oppenheimer boosted their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $90.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.